Translational Research Cancer Centers Consortium Annual Meeting

转化研究癌症中心联盟年会

• 批准号: 8319055
• 负责人: Gregory B. Lesinski
• 金额: $ 0.6万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8319055
• 关键词: Abramson Cancer Center at the University of Pennsylvania; Advertising; Advocate; Anniversary; Appalachian Region; Applications Grants; Area; Automobile Driving; Barbara Ann Karmano Cancer Institute; Biological Response Modifier Therapy; Buffaloes; Cancer Center; Caring; Climate; Clinical; Clinical Research; Clinical Trials; Coal Mining; Collaborations; Communication; Communities; Comprehensive Cancer Center; Data; Development; Education; Fostering; Foundations; Funding; Geographic Locations; Goals; Health Personnel; Health Professional; Hour; Immune system; Immunologics; Immunology; Improve Access; Incidence; Individual; Institutes; Institution; Intention; Internet; Joints; Knowledge; Laboratory Research; Location; Malignant Neoplasms; Michigan; New York; Ohio; Patient Agents; Patients; Pennsylvania; Phase; Physicians; Postdoctoral Fellow; Principal Investigator; Provider; Regional Cancer; Research; Research Personnel; Resort; Roswell Park Cancer Institute; Rural Population; Scientist; Secure; Site; Steel; Students; Therapeutic; Therapeutic Agents; Translating; Translational Research; Uncertainty; Underserved Population; United States; Universities; University of Pittsburgh Cancer Institute; Urban Population; West Virginia; base; cancer immunotherapy; career development; cost; experience; fighting; meetings; member; novel; novel therapeutics; success; symposium

DESCRIPTION (provided by applicant): We are requesting funds to provide partial meeting support for the annual meetings of the "Translational Regional Cancer Center Consortium" or TrC3. The TrC3 is a cancer immunotherapy network, established to promote biologic therapeutics in the Midwestern and Northeastern regions of the United States. For the past 14 years, laboratory and clinical researches from several of this region's cancer centers have met annually in order to exchange information about the research and new clinical trials underway at their respective cancer centers. These centers include: Abramson Cancer Center at the University of Pennsylvania, Barbara Ann Karmanos Cancer Institute at Wayne State University; Case Comprehensive Cancer Center; Mary Babb Randolph Cancer Center at West Virginia University; The Ohio State University Comprehensive Cancer Center; Penn State Cancer Institute; Roswell Park Cancer Institute; University of Pittsburgh Cancer Institute. These cancer centers are well within a couple of hours to a half day driving distance from one another. Therefore, this meeting provides benefit to researchers, physicians, other care providers and their patients in the areas bounded by these groups. Because biologic and immunologic therapy is gaining momentum, this meeting represents an important, accessible, affordable opportunity to obtain information regarding new therapeutic agents, scientific discoveries and clinical trials. This meeting has become a unique experience for various trainees in academic research including students, post-doctoral fellows, residents and other medical personnel to attend a formal scientific meeting, present data and network with experts in the field to establish professional relationships that will aid career development. These annual meetings are held the third week of February at The Seven Springs Resort in Seven Springs, PA. This central meeting site is within a reasonable driving distance from most member institutions. NCI funds will be essential for facilitating early planning, securing our conference facility, CME credit, effective advertising and maintaining an affordable registration rate to allow for trainees and underserved populations an opportunity to attend this meeting. This is especially important due to the uncertainty of institutional and corporate donations in the current financial climate. Securing NCI funds will help us to achieve the following goals of the TrC3: 1) To provide an educational opportunity for researchers and health professionals in the community on data pertinent to the biologic therapy of cancer; 2) To strengthen collaborative research and clinical trials across member institutions that will benefit patients within this geographic region. This effort will be ld by a group of investigators from the consortium including the Principal Investigator: Dr. Gregory Lesinski (Ohio State), and Co-Investigators: Dr. Elizabeth Repasky (RPCI), Dr. Pawel Kalinski (UPMC). Each of these individuals has served as a Course Director for the TrC3 meeting, when it was held at each respective institution. These investigators communicate regularly with and receive guidance from a group of co-organizers from all member cancer centers. PUBLIC HEALTH RELEVANCE: The concept of using the immune system or other biologic therapies to fight cancer is gaining tremendous momentum. This meeting will provide an affordable opportunity for various investigators and trainees from the region to come together to receive vital education on the most recent developments in this field. Furthermore, it will allow for the opportunity to develop joint clinical trials using new promising biologic agents that will e available to patients in geographic regions with a traditionally high incidence of cancer.

描述（由申请人提供）：我们要求资金为“转化区域癌症中心财团”或TRC3的年度会议提供部分会议支持。 TRC3是一个癌症免疫疗法网络，旨在促进美国中西部和东北地区的生物学治疗剂。在过去的14年中，该地区几个癌症中心的实验室和临床研究每年都会相遇，以便在其各自的癌症中心进行有关研究和新的临床试验的信息。这些中心包括：宾夕法尼亚大学的艾布拉姆森癌症中心，韦恩州立大学的芭芭拉·安·卡玛诺斯癌症研究所；病例综合癌症中心；西弗吉尼亚大学的玛丽·巴布·兰道夫癌症中心；俄亥俄州立大学综合癌症中心；宾夕法尼亚州立癌症研究所；罗斯威尔公园癌症研究所；匹兹堡大学癌症研究所。这些癌症中心在几个小时到半天的车程彼此之间良好。因此，本次会议为研究人员，医师，其他护理提供者及其患者提供了好处。由于生物学和免疫学疗法正在增强势头，因此这次会议代表了一个重要，易于访问，负担得起的机会，以获取有关新的治疗剂，科学发现和临床试验的信息。 这次会议已成为各种学术研究学员的独特经历，包括学生，博士后研究员，居民和其他医务人员参加正式的科学会议，与该领域的专家一起介绍数据并网络，以建立有助于职业发展的专业关系。这些年度会议在2月的第三周举行，在宾夕法尼亚州七泉的七个泉水度假村举行。该中央会议地点与大多数会员机构的合理开车距离不在合理的距离之内。 NCI资金对于促进早期计划，确保我们的会议设施，CME信贷，有效的广告和维持负担得起的注册率至关重要，以允许受训人员和服务不足的人群参加这次会议的机会。由于当前财务环境中机构和公司捐赠的不确定性，这尤其重要。确保NCI 资金将帮助我们实现TRC3的以下目标：1）为社区中的研究人员和卫生专业人员提供与癌症生物疗法有关的数据的教育机会； 2）加强会员机构之间的合作研究和临床试验，这将使该地理区域内的患者受益。该联盟的一组研究人员将进行这项工作，包括主要研究员：Gregory Lesinski博士（俄亥俄州立大学）和共同研究人员：Elizabeth Repasky博士（RPCI），Pawel Kalinski博士（UPMC）。这些人中的每个人都在每个机构举行时担任TRC3会议的课程主任。这些研究人员定期与所有成员癌症中心的一组共同组织者进行指导并获得指导。 公共卫生相关性：使用免疫系统或其他生物疗法与癌症作斗争的概念正在获得巨大的动力。这次会议将为来自该地区的各种调查人员和受训者提供一个负担得起的机会，以便在该领域的最新发展中获得重要的教育。此外，它将有机会使用新的有前途的生物学剂进行联合临床试验，这些试验将为传统癌症发病率较高的地理区域患者提供。